Article
A Phase II Efficacy and Safety, Open-Label, Multicenter Study of Imprime PGG Injection in Combination With Cetuximab in Patients With Stage IV KRAS-Mutant Colorectal Cancer.
Clinical colorectal cancer - 1 Sept 2016
Segal Neil H, Gada Purvi, Senzer Neil, Gargano Michele A, Patchen Myra L, Saltz Leonard B
Abstract excerpt
BACKGROUND: Imprime PGG (β(1,6)-[poly-(1,3)-D-glucopyranosyl]-poly-β(1,3)-D-glucopyranose) is an innate immune cell modulator that primes neutrophils and monocytes/macrophages to exert antitumor activity against complement opsonized tumor cells. In patients with KRAS-mutant colorectal cancer (CRC), cetuximab alone is ineffective; however, it can bind to tumor cells and induce opsonization for recognition by...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.